安徽省司尔特肥业股份有限公司公告 安徽省司尔特肥业股份有限公司 关于向公安机关报案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 近日，安徽省司尔特肥业股份有限公司（以下简称"公司"）发现，公司 审计部副部长黄席利等可能涉嫌职务侵占犯罪。在黄席利等拒不配合公司调查 并提出辞职后，公司先后向宣城市公安局经济犯罪侦查支队、宁国市公安局经 济犯罪侦查大队报案。2024 年 1 月 17 日，公司收到宁国市公安局出具的《受 案回执》，案件已受理，受案登记表文号为宁公（经）受案字〔2024〕155 号。 因本次报案案件尚未正式立案，公司目前无法判断案件对本期利润或期后 利润等的影响。公司将全力配合公安机关的侦查工作，维护公司和全体股东利 益，并将根据案件的进展情况，严格按照有关法律、法规及规范性文件的要求 及时履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 特此公告。 安徽省司尔特肥业股份有限公司董事会 二〇二四年一月十八日 证券代码：002538 证券简称：司尔特 公告编号：2024-2 1 ...

安徽省司尔特肥业股份有限公司公告 特此公告。 安徽省司尔特肥业股份有限公司董事会 二〇二四年一月九日 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽省司尔特肥业股份有限公司（以下简称"公司"）董事会于2024年1月6 日收到公司副总经理方君女士提交的书面辞职报告，方君女士原定任期为三 年，至公司第六届董事会任期届满为止，现因个人家庭原因申请辞去公司副总 经理职务，方君女士辞职后将不再担任公司任何职务。 根据《公司法》《公司章程》等有关规定，方君女士的辞职不会对公司的 生产运营产生影响。其辞职报告自送达董事会之日起生效。 截至本公告披露日，方君女士未直接持有公司股份，不存在应当履行而未 履行的承诺事项。 证券代码：002538 证券简称：司尔特 公告编号：2024-1 安徽省司尔特肥业股份有限公司 ...

二、备查文件 关于全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、主要内容 安徽省司尔特肥业股份有限公司（以下简称"公司"）下属全资子公司安徽 司尔特化肥科技有限公司（以下简称"化肥科技"）于近日从全国高新技术企业 认定管理工作领导小组办公室发布的《对安徽省认定机构 2023 年认定报备的第 二批高新技术企业进行备案的公告》获悉，化肥科技被列入安徽省认定机构 2023 年认定报备的第二批高新技术企业备案名单，被认定为高新技术企业，证书编号： GR202334005440，发证日期：2023 年 11 月 30 日。 根据《中华人民共和国企业所得税法》以及国家对高新技术企业的相关税收 优惠政策，化肥科技在通过高新技术企业认定后，连续三年（即 2023 年、2024 年、 2025 年）享受高新技术企业所得税优惠政策，即按 15%的税率缴纳企业所得税。 化肥科技获得该事项认定是对公司在技术研发和自主创新方面的肯定和鼓 励，有助于公司进一步规范经营、科学化管理，提高公司抗风险能力、整体创新 能力和综合竞争力。 安徽省司尔特肥业 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥1,316,913,343.76, representing a 110.58% increase compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥23,123,477.54, a decrease of 286.07% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥34,630,154.52, down 539.52% from the previous year[4] - Total operating revenue for Q3 2023 was CNY 3,034,951,872.96, a decrease of 16.1% compared to CNY 3,616,656,018.52 in the same period last year[22] - Net profit for Q3 2023 was CNY 123,192,854.55, a significant decline of 75.5% from CNY 503,548,484.85 in Q3 2022[24] - Total comprehensive income for the period was CNY 123,192,854.55, compared to CNY 503,548,484.85 in the previous period, indicating a significant decrease[26] - Basic and diluted earnings per share were both CNY 0.14, down from CNY 0.59 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,541,299,762.58, a decrease of 5.79% from the end of the previous year[4] - The company's total assets decreased to CNY 6,541,299,762.58 from CNY 6,943,496,181.91 year-over-year[21] - Total liabilities decreased to CNY 1,290,460,762.01 from CNY 1,597,173,490.89, indicating improved financial stability[21] - The total equity attributable to shareholders was CNY 5,250,839,000.57, down from CNY 5,346,322,691.02[21] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥64,434,914.69, a decline of 122.81% compared to the same period last year[4] - Cash inflow from operating activities totaled CNY 2,748,690,177.46, a decrease from CNY 3,022,412,787.31 in the previous period[28] - Net cash outflow from operating activities was CNY 64,434,914.69, compared to a net inflow of CNY 282,513,166.17 in the previous period[29] - Cash inflow from investment activities was CNY 3,335,053,121.62, up from CNY 2,740,975,267.82 in the previous period[29] - Net cash flow from investment activities was CNY 10,606,389.82, a recovery from a net outflow of CNY 138,579,803.58 in the previous period[29] - Cash inflow from financing activities was CNY 430,000,000.00, while cash outflow was CNY 436,659,381.70, resulting in a net cash outflow of CNY 436,659,381.70[29] - The ending cash and cash equivalents balance was CNY 527,539,990.38, down from CNY 593,174,678.16 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 47.715 million[11] - The largest shareholder, Guogou Industrial Holdings, holds 21.33% of shares, amounting to 182,050,800 shares, with 179,530,000 shares pledged[11] - The top ten shareholders hold a significant portion of shares, with the top two alone accounting for 29.63%[11] Research and Development - Research and development expenses for the first nine months of 2023 were ¥59,988,574.30, down 36.58% from the same period in 2022[9] - The company reported a decrease in research and development expenses to CNY 59,988,574.30 from CNY 94,590,601.60, suggesting a potential shift in focus[24] Future Plans - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[8] - The company plans to invest 1.72448 billion RMB in the construction of a phosphate-fluoride new material integrated industrial park in Guizhou Province, with a construction period of 36 months[15] - The company is actively pursuing market expansion through strategic investments and partnerships in the health and agricultural sectors[14] Financial Management - The company reported a decrease in financial expenses, with interest expenses dropping to CNY 6,673,709.58 from CNY 19,972,727.23, reflecting better cost management[24] - The weighted average return on net assets was -0.44% for the reporting period, down 0.70% year-on-year[4] Audit and Accounting Standards - The company did not undergo an audit for the third quarter report[31] - The company has not adopted the new accounting standards starting from 2023[30]

Financial Performance - The company's revenue for Q3 2023 reached ¥1,316,913,343.76, representing a 110.58% increase compared to the same period last year[4] - The net profit attributable to shareholders was -¥23,123,477.54, a decrease of 286.07% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥45,096,409.32, down 672.36% from the previous year[4] - Total operating revenue for Q3 2023 was CNY 3,034,951,872.96, a decrease of 16.1% compared to CNY 3,616,656,018.52 in the same period last year[22] - Net profit for Q3 2023 was CNY 123,192,854.55, a significant decline of 75.5% from CNY 503,548,484.85 in Q3 2022[24] - Total comprehensive income for the period was CNY 123,192,854.55, compared to CNY 503,548,484.85 in the previous period, indicating a significant decrease[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,541,299,762.58, a decrease of 5.79% compared to the end of the previous year[4] - The company's total assets decreased to CNY 6,541,299,762.58 from CNY 6,943,496,181.91 year-over-year[21] - Total liabilities decreased to CNY 1,290,460,762.01 from CNY 1,597,173,490.89, indicating improved financial stability[21] - The total equity attributable to shareholders decreased to CNY 5,250,839,000.57 from CNY 5,346,322,691.02, reflecting the impact of reduced profits[21] Cash Flow - Cash flow from operating activities showed a net outflow of -¥64,434,914.69, a decrease of 122.81% compared to the same period last year[4] - Net cash flow from operating activities was CNY -64,434,914.69, a decline from CNY 282,513,166.17 in the previous period[29] - Cash inflow from investment activities totaled CNY 3,335,053,121.62, compared to CNY 2,740,975,267.82 in the previous period, showing an increase[29] - Net cash flow from investment activities was CNY 10,606,389.82, recovering from a negative CNY 138,579,803.58 in the previous period[29] - Total cash outflow from financing activities was CNY 436,659,381.70, compared to CNY 802,588,096.47 in the previous period, indicating a reduction[29] - The company reported a cash inflow of CNY 430,000,000.00 from borrowing activities during the current period[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 47.715 million[11] - The largest shareholder, Guogou Industrial Holdings, holds 21.33% of shares, amounting to 182,050,800 shares, with 179,530,000 shares pledged[11] - The top ten shareholders hold a significant portion of shares, with the top two alone accounting for 29.63% of total shares[11] Research and Development - Research and development expenses for the first nine months of 2023 were ¥59,988,574.30, down 36.58% from the same period in 2022[9] - The company reported a decrease in research and development expenses to CNY 59,988,574.30 from CNY 94,590,601.60, suggesting a potential shift in focus[24] Future Plans and Investments - The company plans to invest 1.72448 billion RMB in the construction of a phosphate-fluoride new material integrated industrial park in Guizhou Province, with a construction period of 36 months[15] - The project will include a 600,000 tons/year phosphate ore dressing facility and a 400,000 tons/year sulfuric acid production facility among other installations[15] - The company plans to enhance market expansion efforts and invest in new product development in the upcoming quarters[20] - The company is actively pursuing market expansion through strategic investments and partnerships in the health and materials sectors[14] Operational Efficiency - The company aims to improve operational efficiency and reduce costs further in response to market challenges[20] - Total operating costs for Q3 2023 were CNY 2,914,326,831.86, down from CNY 3,051,351,590.89, reflecting a cost reduction strategy[22] Miscellaneous - As of September 30, 2023, the company's cash and cash equivalents amount to 538.91 million RMB, down from 1.02216 billion RMB at the beginning of the year[18] - The company has provided 110 million RMB in working capital support to a subsidiary, with 40 million RMB remaining to be repaid by the end of 2024[15] - The company has signed a management agreement for its subsidiary, entrusting operations to a local hospital for a period extending until December 31, 2029[16] - The company’s accounts receivable as of September 30, 2023, is 55.41 million RMB, slightly down from 59.74 million RMB at the beginning of the year[18] - The company has not undergone an audit for the third quarter report[31] - The company has not adopted the new accounting standards for the current year[30]

安徽省司尔特肥业股份有限公司公告 一、关联交易基本情况 1、关联交易概述 安徽省司尔特肥业股份有限公司（以下简称"公司"或"甲方三"）、公司 全资子公司安徽省鑫宏大健康产业管理有限公司（以下简称"鑫宏健康公司"或 "甲方二"）、鑫宏健康公司全资子公司宣城华信健康体检门诊部有限公司（以 下简称"华信体检公司"或"甲方二"）（甲方一、甲方二、甲方三统称甲方） 与宣城市骨科医院有限公司（以下简称"骨科医院"或"乙方"）、骨科医院实 际控制人方万鹏（以下简称"丙方一"）、骨科医院股东金平辉（以下简称"丙 方二"）（丙方一、丙方二统称丙方）及骨科医院控股股东宣城东晨健康产业管 理有限公司（以下简称"东晨健康公司"或"丁方"）拟签订《关于宣城华信健 康体检门诊部有限公司之委托管理协议》（以下简称"《委托管理协议》"）， 公司拟将全资孙公司华信体检公司的经营权、管理权委托给骨科医院行使，委托 管理期限自 2023 年 10 月 1 日起至 2029 年 12 月 31 日止，委托管理费用为 300 万元/年。 同时公司、鑫宏健康公司分别与华信体检公司签订资产租赁协议，鑫宏健康 公司将其所有的 GE 心脏彩超、16 排 CT ...

关于签订委托管理协议事项的事前认可及独立意见 安徽省司尔特肥业股份有限公司公告 独立董事：罗忆松 吴玉光 朱克亮 二〇二三年九月二十八日 根据《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》相关法律法规和《公司章程》的有关规定，作为安徽省司尔特肥业股份有限公 司（以下简称"公司"）独立董事，我们对公司签订委托管理协议交易行为进行了 调查和了解，基于独立判断的立场，发表独立董事意见如下： 安徽省司尔特肥业股份有限公司独立董事 上述交易事项在提交董事会审议时，经过我们事前认可。本次交易有利于公司 进一步聚焦主营业务，整合和优化资源配置，帮助公司提升盈利能力、降低经营风 险，符合公司长远规划，符合公司和全体股东的利益。本次交易价格由公司与交易 对方在公平、自愿的原则下协商确定，定价合理，不存在损害公司及其全体股东、 特别是中小股东利益的情形。本次交易事项的决策程序符合《公司法》等相关法律、 法规及《公司章程》 的有关规定，决策程序合法合规。因此，我们一致同意此项议 案。 ...

证券代码：002538 证券简称：司尔特 公告编号：2023-37 安徽省司尔特肥业股份有限公司 安徽省司尔特肥业股份有限公司公告 安徽省司尔特肥业股份有限公司（以下简称"公司"或"本公司"）第六届董事 会第十一次（临时）会议于 2023 年 9 月 28 日在公司七楼会议室以现场结合通讯 方式召开，会议通知于 2023 年 9 月 23 日以专人送达及电子邮件方式送达。本次 会议应到董事 9 名，实到董事 9 名；公司全体监事和部分高级管理人员列席本次 会议，会议由公司董事长朱国全先生主持。本次会议符合《公司法》《公司章程》 的规定，会议的召集、召开合法有效。经与会董事审议表决，形成如下决议： 审议通过《关于签订委托管理协议暨关联交易的议案》 同意公司签订《关于宣城华信健康体检门诊部有限公司之委托管理协议》， 将全资孙公司宣城华信健康体检门诊部有限公司的经营权、管理权委托给宣城市 骨科医院有限公司行使，委托管理期限自 2023 年 10 月 1 日起至 2029 年 12 月 31 日止，委托管理费用为 300 万元/年。 投票结果：全体董事以 9 票赞成，0 票反对，0 票弃权通过该议案。 内容详见 20 ...

安徽省司尔特肥业股份有限公司公告 截至本公告披露日，文继兵先生未直接持有公司股份，不存在应当履行而未 履行的承诺事项。 特此公告。 安徽省司尔特肥业股份有限公司董事会 二〇二三年九月二十日 安徽省司尔特肥业股份有限公司 关于副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 安徽省司尔特肥业股份有限公司（以下简称"公司"）董事会于2023年9月19 日收到公司副总经理文继兵先生提交的书面辞职报告，文继兵先生因个人原因申 请辞去公司副总经理职务及其在公司各分公司、子公司担任的全部职务，辞职后 将不再担任公司任何职务。 根据《公司法》《公司章程》等有关规定，文继兵先生的辞职不会影响公司 经营正常运行，其辞职报告自送达董事会之日起生效。公司董事会对文继兵先生 在任职期间做出的工作表示感谢！ 证券代码：002538 证券简称：司尔特 公告编号：2023-36 ...

鉴于公司原董事的离职和新董事的选举产生，同意变更公司各专门委员会的 成员，变更后的公司董事会专门委员会成员组成情况如下： （1）战略委员会 安徽省司尔特肥业股份有限公司公告 证券代码：002538 证券简称：司尔特 公告编号：2023-35 安徽省司尔特肥业股份有限公司 第六届董事会第十次（临时）会议决议公告 本公司及其董事会全体成员保证公告内容真实、完整和准确，不存在虚假 记载、误导性陈述或重大遗漏。 安徽省司尔特肥业股份有限公司（以下简称"公司"或"本公司"）第六届董事 会第十次（临时）会议于 2023 年 9 月 6 日在安徽省合肥市汇金大厦 26 楼 1 号会 议室以现场结合通讯方式召开，会议通知于 2023 年 9 月 6 日 2023 年第二次股东 大会审议通过后以专人送达及电子邮件方式送达。本次会议应到董事 9 名，实到 董事 9 名；公司全体监事和部分高级管理人员列席本次会议，会议由公司董事长 朱国全先生主持。本次会议符合《公司法》《公司章程》的规定，会议的召集、 召开合法有效。经与会董事审议表决，形成如下决议： 审议通过《关于变更第六届董事会专门委员会成员的议案》 主任委员：吴玉光（独立董事 ...